LX2931
Based on 1 Customer Validation
LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the study of autoimmune diseases, especially rheumatoid arthritis.
For research use only. We do not sell to patients.
- Purity : 98.88%
- CAS No.: 948840-25-3
- Formula: C9H15N3O5
- Molecular Weight:245.23
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-12355
SiponimodS1P1/S1P5 Agonist -
HY-12288
OzanimodS1P Receptor Modulator -
HY-12789
EtrasimodS1P1 Receptor Antagonist -
HY-19736
TY-52156LPL Receptor Antagonist -
HY-10569
PonesimodS1P1 Agonist -
HY-101419
CYM-5541S1P3 Receptor Agonist -
HY-108490
VPC 23019S1P1/3 Antagonist -
HY-15382
FTY720 (S)-PhosphateLPL Receptor Agonist -
HY-115831
SAR247799S1P1 Agonist -
HY-101265
IcanbelimodS1P Receptor Agonist -
HY-108495
CYM50308S1P4 Receptor Agonist -
HY-12288A
Ozanimod hydrochlorideS1P Receptor Modulator
Biological Activity
Description
Chemical Information
-
CAS No. 948840-25-3
-
Appearance Solid
-
Molecular Weight 245.23
-
Formula C9H15N3O5
-
Color White to off-white
-
SMILES
OC[C@@H](O)[C@@H](O)[C@@H](C1=CN=C(/C(C)=N/O)N1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (407.78 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bagdanoff J T, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1 R, 2 S, 3 R)-1, 2, 3, 4-tetrahydroxybutyl)-1 H-imidazol-2-yl) ethanone oxime (LX2931) and (1 R, 2 S, 3 R)-1-(2-(isoxazol-3-yl)-1 H-imidazol-4-yl) butane-1, 2, 3, 4-tetraol (LX2932)[J]. Journal of medicinal chemistry, 2010, 53(24): 8650-8662. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0778 mL | 20.3890 mL | 40.7780 mL | 101.9451 mL |
| 5 mM | 0.8156 mL | 4.0778 mL | 8.1556 mL | 20.3890 mL | |
| 10 mM | 0.4078 mL | 2.0389 mL | 4.0778 mL | 10.1945 mL | |
| 15 mM | 0.2719 mL | 1.3593 mL | 2.7185 mL | 6.7963 mL | |
| 20 mM | 0.2039 mL | 1.0195 mL | 2.0389 mL | 5.0973 mL | |
| 25 mM | 0.1631 mL | 0.8156 mL | 1.6311 mL | 4.0778 mL | |
| 30 mM | 0.1359 mL | 0.6796 mL | 1.3593 mL | 3.3982 mL | |
| 40 mM | 0.1019 mL | 0.5097 mL | 1.0195 mL | 2.5486 mL | |
| 50 mM | 0.0816 mL | 0.4078 mL | 0.8156 mL | 2.0389 mL | |
| 60 mM | 0.0680 mL | 0.3398 mL | 0.6796 mL | 1.6991 mL | |
| 80 mM | 0.0510 mL | 0.2549 mL | 0.5097 mL | 1.2743 mL | |
| 100 mM | 0.0408 mL | 0.2039 mL | 0.4078 mL | 1.0195 mL |
LX2931 Related Classifications
HY-14370 Related Classifications
Powered by Bioz